Form 4: Halozyme Director Mahesh Krishnan Receives Equity Grant

Director Mahesh Krishnan was granted 3,796 restricted stock units and 6,040 stock options as part of Halozyme Therapeutics' annual director compensation program.

Summary

• Director Mahesh Krishnan acquired 3,796 restricted stock units (RSUs) on May 5, 2026.
• Director Mahesh Krishnan was granted 6,040 stock options with an exercise price of $65.87 on May 5, 2026.
• The total beneficial ownership for the director following these transactions is 14,462 shares of common stock.
• Both the RSU and option grants are scheduled to vest on the earlier of May 5, 2027, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized annual compensation grant indicates stable corporate governance practices.

Negatives

• Dilutive impact of new equity grants, though standard for director compensation.

Risks

• Market price volatility affecting the value of the granted options.
• Vesting is contingent upon continued service as a director.

Future Outlook

The grants are part of the standard annual director compensation program and do not signal specific strategic shifts.

Industry Context

StockSavvy.ai notes that annual equity grants for board members are standard practice in the biotechnology sector to ensure long-term alignment between independent directors and shareholder value.

Comparison to Industry Standards

• The grant structure is consistent with typical compensation packages for non-employee directors in mid-cap biotech firms.
• Vesting schedules of one year are standard for annual director equity awards.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on May 5, 2027, or the next annual meeting.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Form 4, Director Compensation, Insider Transaction, Equity Grant